xalkori | Pharma Strategy Blog

ASCO 2012 Update 1: Advanced Lung Cancer

By MaverickNY on June 26, 2012

ASCO 2012 Outside Arie Crown 300x225 ASCO 2012 Update 1: Advanced Lung Cancer It’s been a crazy busy time since the American Society of Clinical Oncology (ASCO) meeting earlier this month.

This year’s meeting had a lot of hidden gems in both the tumour oral and poster sessions, which will be covered in a series of blog posts.

One theme that clearly emerged was how much effort is being devoted to identifying the causes of acquired resistance to a variety of TKI single agent therapies in order to determine logical combination strategies for the clinic.

Two areas that stood out for their combined translational-clinical efforts at this years ASCO were advanced lung cancer and metastatic melanoma.

This is a preview of ASCO 2012 Update 1: Advanced Lung Cancer. Read the full post

On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer

By MaverickNY on March 23, 2012

One of the biggest challenges facing cancer research was aptly summarised by Levi Garraway and Pasi Jänne in this month’s Cancer Discovery journal:

“All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance.”

It will therefore come as no surprise to PSB readers that resistance occurs with two drugs approved by the FDA only last year; vemurafenib (BRAFV600E melanoma) and crizotinib (ALK+ lung cancer). We’ve discussed the development of resistance in melanoma here via several potential mechanisms in the past and potential strategies for overcoming them (eg MEK inhibitors), but what about lung cancer?

This is a preview of On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer. Read the full post

2 Comments

When is NICE is not so nice?

By MaverickNY on October 14, 2011

“Ipilimumab is not recommended for the treatment of advanced (unresectable or metastatic) malignant melanoma in people who have received prior therapy.

The Committee was satisfied that ipilimumab meets the criteria for being a life-extending, end-of-life treatment and that the trial evidence presented for this consideration was robust.

The Committee acknowledged that few advances had been made in the treatment of advanced melanoma in recent years and ipilimumab could be considered a significant innovation for a disease with a high unmet clinical need.

This is a preview of When is NICE is not so nice?. Read the full post

My take on the crizotinib Xalkori FDA approval

By MaverickNY on August 26, 2011

Pfizer’s Crizotinib (Xalkori) approved in ALK-positive lung cancer!

The FDA just announced that they have approved Pfizer’s crizotinib (Xalkori):

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

Xalkori is being approved with a companion diagnostic test that will help determine if a patient has the abnormal ALK gene, a first-of-a-kind genetic test called the Vysis ALK Break Apart FISH Probe Kit. It is the second such targeted therapy approved by the FDA this year.

This is a preview of My take on the crizotinib Xalkori FDA approval. Read the full post

13 Comments

The spiralling costs of cancer research and treatment

By MaverickNY on August 23, 2011

“The problem at the moment is that it takes $1bn [£600m] to get a drug to market and 15 years or more. That is the justification for the pharmaceutical industry charging high prices.

If on the other hand by the time you get to phase 2 you know exactly which patients it is going to work on, you only put those patients through and instead of 10% you get an 80% response rate.

This is a preview of The spiralling costs of cancer research and treatment. Read the full post

9 Comments

Seattle Genetics announce fast track approval of Adcetris

By MaverickNY on August 22, 2011

This morning, Seattle Genetics announced that the expected fast track approval from the FDA has been forthcoming for brentuximab vedotin (Adcetris) following the recent unanimous ODAC voting in both refractory Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL). Clearly, the company and the agency have come to agreement on the confirmatory trials as part of the condition of accelerated review. The final prescribing information (PI) can be found on the Adcetris website.

For those of you looking for more information on Adcetris, please check out the related posts section below for previous reports on this novel ADC therapy.

This is a preview of Seattle Genetics announce fast track approval of Adcetris. Read the full post